Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00484198 · ClinicalTrials.gov registry record · Phase 3

Study of Rivoglitazone in Type 2 Diabetes Mellitus

A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 3
Development phase
1,912
Enrollment target
20
Study locations

NCT00484198: Completed Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Daiichi Sankyo.

NCT00484198 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,912 participants, below the 2,945-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00484198, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 3
Development phase
1,912 participants
Enrollment target
20
Study locations

Study Summary

This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period.

Primary Outcome

Percentage of hemoglobin A1c (HbA1c) levels are reported.

Conditions Studied

Type 2 Diabetes Mellitus

Interventions

  • DRUG Placebo
  • DRUG Pioglitazone
  • DRUG Rivoglitazone

Study Locations (20)

California

  • - Buena Park
  • - Garden Grove
  • - Huntington Park
  • - Los Angeles
  • - Paramount
  • - Sacramento
  • - San Diego
  • - Walnut Creek
  • - West Covina
  • - West Hills

Alabama

  • - Anniston
  • - Birmingham
  • - Hoover
  • - Muscle Shoals

Arkansas

  • - Hot Springs
  • - Jonesboro
  • - Little Rock

Florida

  • - Delray Beach
  • - Jacksonville

Colorado

  • - Denver

Trial Details

FieldValue
Enrollment Target 1,912 participants
Start Date 2007-04-23
Est. Completion 2009-02-12
Phase Phase 3
Daiichi Sankyo

236 total trials

What the finished NCT00484198 record still lists

NCT00484198 is an interventional study that assigns participants to a tested intervention. Its 1,912 participants enrollment target places it among the larger protocols in the corpus, below the 2,945-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (35% lower).

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00484198 names 20 study sites across 5 states, led by California, Alabama, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00484198 about?

NCT00484198 is a clinical study titled "Study of Rivoglitazone in Type 2 Diabetes Mellitus". This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26...

What is the current status of trial NCT00484198?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,912 participants. The study started on 2007-04-23. Estimated completion is 2009-02-12.

What conditions does trial NCT00484198 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT00484198?

The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Rivoglitazone (DRUG).

Who is sponsoring clinical trial NCT00484198?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00484198 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00484198's enrollment target sits among peer trials

1,912 9th of 130 higher than 122 of 130 other Type 2 Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05174169 · 1,912 participants · Phase 2

    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  • NCT06799117 · 1,912 participants · NA

    Adaptive Decision Support for Addiction Treatment Master

  • NCT06058455 · 1,920 participants · NA

    An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)

  • NCT03729180 · 1,900 participants · NA

    The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00484198, the US trial registry maintained by the National Library of Medicine. NCT00484198 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.